MedTrace Logo

Hypothermia Risk With Continuous Renal Replacement Therapy

NCT03973814 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-12-22

No results posted yet for this study

Summary

The present study aims at testing if the TherMax blood warmer is more accurate and reliable in reaching and maintaining chosen target temperature during continuous renal replacement therapy as compared to the Prismaflo IIS blood warmer used for the PrismaFlex system.

Conditions

Interventions

DEVICE

Thermax Blood Warmer

Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.

Sponsors & Collaborators

  • Skane University Hospital

    collaborator OTHER

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Max Bell, MD, PhD · Karolinska University Hospital

  • Marcus Broman, MD, PhD · Skane University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-12-21
Completion
2023-12-21
FDA Device
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03973814 on ClinicalTrials.gov